Upper Management must not care about the reps if they have made the decision to kill Fuse. These accounts that bought Fuse believed in the technology and now they are going to be purchasing another system when their current agreement runs out. Before all the asshats come out and say it was a POS, which it was in the beginning, it turned into something to be proud of. I can only hope these accounts that are getting screwed take it out on BSC and start converting business away from their order taking reps.
These customers aren't getting screwed by BSC. They are getting screwed by their colleagues who didn't have the foresight or capability to embrace a technology that will provide better outcomes to their patients. Additionally, the blame for Fuse being shelved falls on those who decided to introduce it before it was ready and price it irresponsibly. You were clearly a BSC hater before this all took place, so have some self awareness.
Awareness?! Haha. This falls squarely on the shoulders of BSC. They are the ones pulling the plug. It doesn't matter what happened prior or how Fuse was introduced. Customers were buying it and the believed in the technology. Hater? Maybe...but at the end of the day customers aren't going to be happy at this decision.
Just an FYI, but several of the previous Endochoice executives had found a buyer for Fuse offering good money for it. But of course Boston saw a greater financial opportunity to write the loss off rather than sell it. Tell me again how Boston is committed to advancing the healthcare of their patients. The only thing Boston sci gives a damn about is that bottom line dollar. They don't give a shit about their customers or patients. The ego from this organization is astounding which is ironic since it's a break into medical company. FYI, most physicians and nurses think you guys are assholes who try to pretend you're just as valuable as the physician.
Agreed. When Boston bought EC, it became evident they were only interested in the pathology. They don't see the value in the kits or scope repair for that matter. Fuse is/was a game changer and they are too short sighted to see it. To the poster above that said the reason it was shelved was bc of how it was introduced...what?! Please explain how the introduction of Fuse has anything to do with why its being killed off. I know of three Fuse accounts personally who are looking to convert everything bc of this decision. BSC reps are nothing but glorified order takers. When is the last time they have actually sold a new product? They couldn't sell Spy DS so they resorted to giving it way when bundled with other products. These docs re constantly laughing at y'all when you leave the room. You didn't go to med school but stand in an ERCP telling them what to do and how to do it.
Wow, finally some truth comes to the Café. Fuse was and is a game changer. Fuse was launched too early and BSC is killing it, because they can’t recognize an ROI that will keep the stock holders happy. You will see a wide angle scope within the next 18 months and it will fly off the shelves, because it has a Big (yet dirty and tarnished name behind it). Physicians will be more comfortable getting behind it, because they are afraid to venture into the unknown. EndoChoice was an unknown and now there is a momentum that can’t be stopped (not to mention an infrastructure that can scale its demand). If Fuse had been launched properly/ready for launch, then the uptick would have been faster and the head wind would not have been so strong early on. The question is, would this have gotten Fuse to a profitable position, before MG began talking with BSC? Who knows, probably not. This would have required a perspective, other than the one leadership had and the patients to slow things down and do the right thing. Unfortunately, what we have seen here is; a great idea/technology put to rest- due to the economics of medicine and the overpowering drive for cash, over patient care. No matter how you look at it, money talks and Fuse was not speaking loud enough. Those interested in its continuation, could not figure out a way for the money to come fast enough; to appease those loaning the money. Vicious cycle for the little guy and insurance for the big players. Luckily, BSC got themselves a path company. Hopefully we will be able to learn a thing or two about customer service and not lose all the business EC employees EARNED.
Interesting discourse. I am a registered nurse (GI, ICU) and curious to find out if there are issues with the Fuse endoscope needing frequent repair to the distal tip. Had a patient with significant perforation in the distal sigmoid in the hands of an experienced endoscopist, without bx or polypectomy. I have been told that the Fuse scope has been sent for frequent repairs due to distal tip malfunction causing sharp edges. If anyone can shed some light it would be appreciated.
I visited this site to try to find information on Fuse, since our Endo unit purchased the system and have been having major issues with repairs as well. Thankfully no patient injury; I hope this is investigated, but I have my doubts as our service and support has been a real issue ever since our rep left the company after Boston Scientific took over. Trust in this company in our facility is gone. Our physicians are extremely upset, and are already shopping for a replacement after only 2 years!
That was an issue with Fuse prior to the acquisition. Sucks to hear that it is still happening. We(Endochoice) had a class two recall of our scopes in December, 2015 and I thought we addressed that problem back then? I guess not. The problem was a combination of two things: 1. When Endochoice was building their version two scope(V2), the tips of the scope were from version one. The two components didn't match up perfectly so you'd get these distal tip separations (I viewed at least three at one of my Fuse accounts). 2. Instead of using an adhesive to join the distal tip and the body of the scope together, Endochoice used a spot weld at the tip. Over time, those areas would weaken/break and the tips would separate.
